Clinical Trials

Anetumab Ravtansine Fails to Show Improvement of Progression-Free Survival in Mesothelioma

In a statement released on Sunday, Bayer announced that Anetumab ravtansine, its antibody-drug conjugate (ADC) tested in mesothelioma, has missed its primary endpoint failing to improve progression-free survival in mesothelioma patients.
“Malignant pleural mesothelioma is a very difficult-to-treat tumor, and we had hoped for a better outcome for patients,” said Robert LaCaze, Executive Vice President and […]


“There’s no question that research cures cancer”

“There’s no question that research cures cancer,” began Dr. Rich Alexander of the University of Maryland and chair of the Meso Foundation’s Board of Directors. “If you look at the most effective therapies that we have now for many cancers across the country, those treatments were defined through the clinical trials process.”
At the 2017 International […]


BREAKING NEWS FROM ASCO: Avelumab Results for Mesothelioma Treatment Released

Dr. Raffit Hassan of the National Cancer Institute, and former chair of the Mesothelioma Applied Research Foundation’s Science Advisory Board, announced results of the Phase 1 clinical trial of avelumab at the most recent ASCO (American Society of Clinical Oncology) meeting in Chicago.
Avelumab, an anti-PD-L1 antibody, works on the basis of boosting the immune system. […]


Despite Negative Results, Meso Foundation Grateful for Investment Into Disease

The Meso Foundation released a statement from its executive director, Mary Hesdorffer, APRN, about AstraZeneca’s tremelimumab trial for mesothelioma.
In an AstraZeneca press release issued yesterday, the company states that “DETERMINE, the Phase IIb clinical trial of 10 mg/kg tremelimumab monotherapy in second or third-line treatment of unresectable malignant mesothelioma, did not meet its primary endpoint […]


Pharmaceutical Company Completes Enrollment for Phase 1B Trial for Mesothelioma

If you attended our International Symposium on Malignant Mesothelioma in March of this year, you may recall the buzz of excitement that coursed throughout the scientific sessions. This buzz sparked excitement throughout the entire mesothelioma community, as we discussed advances in science, the needs of those affected by this disease, and the work being done […]